Fujirebio Holdings, Inc., a global leader in diagnostic technologies, and Agappe Diagnostics Ltd, a well-established name in the Indian medical diagnostic industry, have entered into a landmark agreement that aims to revolutionize the immunoassay market in India.
The collaboration focuses on the Contract Development and Manufacturing Organization (CDMO) partnership, targeting the production of Cartridge-based Chemiluminescence Immunoassay (CLIA) system reagents. This partnership aligns with both companies’ vision of advancing healthcare standards and making high-quality diagnostic solutions more accessible across India.
A Partnership to Drive Innovation in Immunoassay Solutions
Announced on January 19, 2024, the agreement between Fujirebio and Agappe Diagnostics marks a significant milestone in the development of immunoassay technology in India. The project centers on the production of reagents for the CLIA-based systems, Mispa i60 and Mispa i121.
Notably, this collaboration will see Agappe become the first Indian company to offer a complete Chemiluminescence Solution, manufactured entirely with locally sourced reagents. This development positions Agappe as a pioneer in the domestic market, emphasizing the growing importance of local manufacturing in India’s healthcare ecosystem.
The project has made substantial progress, including the signing of a Supply and License Agreement in March 2023, and the technical transfer process is already underway.
Agappe is leveraging Fujirebio’s advanced technology and materials to ensure the seamless production of Chemiluminescence Reagents, setting the stage for a June 2024 product launch.
The comprehensive range will span over 30 parameters across various medical segments, including Oncology, Thyroid, Cardiac, Fertility, and Infectious Diseases.
In addition to conventional diagnostic areas, Fujirebio’s cutting-edge biomarkers for neurodegenerative diseases, such as Alzheimer’s, will also be a part of this collaboration. By introducing these advanced diagnostic tools to the Indian market, both companies are setting new benchmarks for healthcare innovation in the country.
Expanding the Immunoassay Market in India
The partnership between Fujirebio and Agappe is driven by a shared vision of transforming the immunoassay landscape in India. Fujirebio, known for its innovations in diagnostic technologies, will provide the CLIA equipment, including the Mispa i60 and i121 analyzers, along with reagent raw materials.
Meanwhile, Agappe will take charge of the development and manufacturing of dedicated reagents tailored to these machines. This arrangement ensures that the products will adhere to all necessary regulatory requirements, further cementing the collaboration’s role in expanding India’s immunoassay market.
One of the most noteworthy aspects of this collaboration is its potential to make diagnostic solutions more cost-effective and accessible to a wider population. India, being one of the fastest-growing healthcare markets globally, stands to benefit from this partnership, as it brings together Fujirebio’s technological expertise and Agappe’s deep understanding of the local market.
Goki Ishikawa, President and CEO of Fujirebio Holdings, emphasized the significance of the collaboration, stating, “This partnership with Agappe, the renowned market leader with years of success in Clinical Chemistry, Hematology, Immunochemistry, and Point of Care in India, will accelerate our CDMO strategy in one of the most important and fastest-growing countries in the world.”
Thomas John, Managing Director of Agappe Diagnostics, echoed this sentiment, underlining the joint commitment to innovation and accessibility.
“Leveraging the combined strengths of Agappe and Fujirebio, we are committed to introducing high quality, affordable, and unique Chemiluminescence solutions for the country.
This partnership symbolizes our dedication to innovation and our pledge to make advanced diagnostic products more accessible to every Indian.”
A Vision for Healthcare Advancement in India
At the core of this collaboration is a mutual belief that the combined strengths of Fujirebio and Agappe will not only drive growth in the immunoassay market but also contribute significantly to the advancement of healthcare in India.
Both companies share a vision of developing diagnostic solutions that are not only innovative but also affordable, meeting the needs of the Indian population at large.
Fujirebio’s global experience in developing biomarkers and in vitro diagnostic technologies, paired with Agappe’s local expertise, positions this partnership as a game-changer in the Indian healthcare market.
The phased launch of products, which will begin in June 2024, will provide healthcare providers across the country with access to advanced diagnostic tools, enabling earlier and more accurate detection of diseases across multiple segments.
This initiative underscores the importance of collaboration between global leaders and local companies in addressing the healthcare challenges of emerging markets.
By focusing on locally manufactured reagents and leveraging Fujirebio’s innovative technologies, this partnership sets a new precedent for how healthcare solutions can be developed and distributed in India.
About Fujirebio and Agappe
Fujirebio, a member of H.U. Group Holdings Inc., is a global research-driven company that specializes in the development of unique biomarkers and in vitro diagnostics.
With a mission to create new value in healthcare, Fujirebio is committed to advancing human health through cutting-edge diagnostic solutions.
Agappe Diagnostics, Ltd is a leading Indian company specializing in Clinical Chemistry, Hematology, Immunochemistry, and Point of Care diagnostics.
With a track record of success in the healthcare industry, Agappe remains dedicated to providing innovative, affordable, and accessible diagnostic solutions across India.
The collaboration between Fujirebio and Agappe marks a new era in the immunoassay market in India.
By combining global expertise with local insights, this partnership not only promises to introduce advanced diagnostic technologies but also reinforces the importance of accessible healthcare solutions.
As the project progresses and the products launch in June 2024, the Indian healthcare sector is poised to benefit from the high-quality, cost-effective solutions that Fujirebio and Agappe are set to deliver.
